Public Academic References

Public research context for AI and life science judgment

This page curates public sources from award organizations, regulators, research institutions, and published research context. It does not imply collaboration, advisory status, authorization, residency, or endorsement by the referenced experts or institutions.

Citation Principle

Citing public facts without implying endorsement

AIBIOOS separates company team members from public academic references. Team representation requires explicit authorization and real collaboration; references are used only to describe scientific direction, research trends, and regulatory context.

For that reason, this page does not use unauthorized portraits, expert-profile cards, institutional logos, or language that suggests advisory, resident, or endorsement relationships.

The experts, awards, publications, and institutional materials referenced on this page are curated from public sources for scientific context only. Unless explicitly stated otherwise, the referenced experts, institutions, award organizations, and research teams have no collaboration, advisory, authorization, residency, or endorsement relationship with AIBIOOS.

AI for Science

Computational protein design and structure prediction

David Baker, Demis Hassabis, and John Jumper received the 2024 Nobel Prize in Chemistry for work related to computational protein design and protein structure prediction.

For AIBIOOS, this progress shows how AI can participate across molecular structure, mechanistic reasoning, and research workflow organization.

Source: Nobel Prize, Chemistry 2024

Gene Editing

CRISPR/Cas9 and life science tool systems

Emmanuelle Charpentier and Jennifer Doudna received the 2020 Nobel Prize in Chemistry for the CRISPR/Cas9 genome editing method.

It suggests that platform-oriented life science companies should focus on tools, data, validation, and regulatory boundaries rather than isolated product concepts.

Source: Nobel Prize, Chemistry 2020

Translational Medicine

mRNA platforms and deployable health technology

Katalin Kariko and Drew Weissman received the 2023 Nobel Prize in Physiology or Medicine for discoveries related to nucleoside base modifications.

The case reinforces AIBIOOS's focus on coordinated research, data, process, validation, and application context rather than concept packaging.

Source: Nobel Prize, Physiology or Medicine 2023

Cell Engineering

Cell reprogramming and regenerative medicine

John B. Gurdon and Shinya Yamanaka received the 2012 Nobel Prize in Physiology or Medicine for showing that mature cells can be reprogrammed to become pluripotent.

It provides long-term context for organoids, disease models, individualized research, and longitudinal health management.

Source: Nobel Prize, Physiology or Medicine 2012

Stress Biology

Oxygen sensing and chronic disease frameworks

William G. Kaelin Jr., Peter J. Ratcliffe, and Gregg L. Semenza received the 2019 Nobel Prize in Physiology or Medicine for discoveries on how cells sense and adapt to oxygen availability.

Such mechanisms help the platform maintain scientific boundaries in health communication and avoid presenting early exploration as established efficacy.

Source: Nobel Prize, Physiology or Medicine 2019

Regulatory Science

New approach methodologies and human-relevant evidence

FDA continues to advance new approach methodologies, including advanced in vitro systems, computational modeling, and human-relevant evidence generation in drug development and safety assessment.

This aligns with AIBIOOS's interest in AI, organoids, data modeling, and translational validation.

Source: FDA, New Approach Methodologies